Business Context and Reporting Period
InterCure Ltd., a foreign private issuer based in Herzliya, Israel, filed Form 6-K on May 1, 2025. The filing disseminates a press release announcing full-year 2024 financial results and providing an update for the first quarter of 2025.
Key Financial Metrics
- Revenue (FY2024): NIS 239 Million
- Adjusted EBITDA (FY2024): NIS 24 Million
- Q1 2025 Performance: Described by management as a "Strong Start," though specific numerical values for Q1 2025 are not provided in the filing text.
- Other Metrics: The filing text does not provide clear values for net profit, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes
The filing text does not provide comparative data for the prior period (FY2023) or specific percentage changes in revenue or profitability. Consequently, material changes versus the prior comparable period cannot be quantified from this document alone.
Guidance, Outlook, and Risks
Management commentary highlights a "Strong Start to 2025" based on Q1 performance. The filing does not contain specific forward-looking guidance, detailed risk factors, contingencies, or disclosures of unusual items beyond the general announcement of results.
Investor Verification Checklist
- Verify the specific Q1 2025 revenue and EBITDA figures referenced in the "Strong Start" commentary by reviewing the full press release (Exhibit 99.1).
- Confirm the year-over-year growth rates for FY2024 revenue and Adjusted EBITDA against FY2023 results.
- Review the full financial statements to assess cash flow, debt obligations, and liquidity positions not detailed in this summary.
- Examine the reconciliation of Adjusted EBITDA to net income to understand non-GAAP adjustments.